Monitoring Arrhythmias Using Medtronic LINQ-2 Device in Patients Starting Bruton Tyrosine Kinase Inhibitors for Blood Cancers

What this Trial Is About

Researchers are evaluating the use of Medtronic LINQ-2 insertable cardiac monitors ILR to detect new onset atrial fibrillation AF and other arrhythmias in patients starting treatment with Bruton Tyrosine Kinase BTK inhibitors. This study aims to understand how often arrhythmias develop during BTK inhibitor therapy and what actions are taken when arrhythmias are detected. The study is prospective and non-blinded and focuses on patients without prior documented arrhythmias. The study involves implanting the Medtronic LINQ-2 cardiac monitor in 50 patients who are beginning BTK inhibitor treatment for approved conditions such as chronic lymphocytic leukemia. The device is implanted by a certified electrophysiologist at least 24 hours before starting BTK therapy. Patients will be monitored continuously with the device for up to 60 months or until they withdraw consent or have the device removed. Participants will be remotely monitored for arrhythmias during the study period. Researchers will record incidence rates of atrial fibrillation and ventricular arrhythmias at 18 months and long-term up to 60 months. They will also track any changes to BTK inhibitor dosing, initiation of anticoagulation, and clinical actions resulting from device-detected arrhythmias. The study includes regular data collection from device monitoring and chart reviews to assess outcomes and safety.

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors